In vitro and in vivo experiments utilizing the EGFR/HER2 double-positive bladder cancer cell line SW-780 showed more potent effects upon combinatorial treatment in comparison to mono treatments (187). This evidence concerns the gene EGFR and urinary bladder carcinoma.